Symbiotec Pharmalab Ltd (SYMBIOTEC) — Announcement | 30 September 2026

Symbiotec Pharmalab announced that its wholly owned subsidiary Knovea Pharmaceutical has entered a strategic commercialization agreement with a leading global pharmaceutical company to launch two Dual Chamber Vial injectable products in the U.S. market, estimated at $288 million. Knovea will manage development, regulatory filings, manufacturing and supply, while the partner handles U.S. commercialization and distribution. The agreement includes milestone payments and profit-sharing, positioning Knovea as a key player in complex injectables with high barriers to entry. This partnership validates Knovea's DCV platform technology and opens pathways for future collaborations, enhancing its growth prospects in the U.S. market.